发布求助
文献互助 智能选刊 最新文献

Drugs of The Future最新文献

筛选
英文 中文
Lisavanbulin. Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme Lisavanbulin。微管不稳定剂(微管蛋白聚合抑制剂)，肿瘤检查点控制器，多形性晚期胶质母细胞瘤的治疗
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.9.3417140
C. Tiu, J. López
{"title":"Lisavanbulin. Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme","authors":"C. Tiu, J. López","doi":"10.1358/dof.2022.47.9.3417140","DOIUrl":"https://doi.org/10.1358/dof.2022.47.9.3417140","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66445381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sabatolimab. TIM-3-targeting monoclonal antibody, Treatment of myelodysplastic syndrome, Treatment of acute myeloid leukemia Sabatolimab。tim -3靶向单克隆抗体，治疗骨髓增生异常综合征，治疗急性髓性白血病
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.5.3378054
M. Ussowicz
{"title":"Sabatolimab. TIM-3-targeting monoclonal antibody, Treatment of myelodysplastic syndrome, Treatment of acute myeloid leukemia","authors":"M. Ussowicz","doi":"10.1358/dof.2022.47.5.3378054","DOIUrl":"https://doi.org/10.1358/dof.2022.47.5.3378054","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Chemical Society - 263rd National Meeting and Exposition. Virtual/San Diego - March 20-24, 2022 美国化学学会第263届全国会议暨博览会。虚拟/圣地亚哥——2022年3月20-24日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.5.3432776
A. Fernández-Llamazares, S.K. Chadrasekaran, P. Cole, X. Bofill
{"title":"American Chemical Society - 263rd National Meeting and Exposition. Virtual/San Diego - March 20-24, 2022","authors":"A. Fernández-Llamazares, S.K. Chadrasekaran, P. Cole, X. Bofill","doi":"10.1358/dof.2022.47.5.3432776","DOIUrl":"https://doi.org/10.1358/dof.2022.47.5.3432776","url":null,"abstract":"The American Chemical Society (ACS)'s National Meeting and Exposition is a premier networking and education event for the global chemistry community, with an astounding program of scientific sessions covering all fields of chemistry. The 263rd edition of ACS meeting, with the theme 'Bonding through chemistry,' was held both on site at the San Diego Convention Center and virtually allowing for an almost return to normal meeting attendance since the start of the COVID-19 pandemic. The meeting spanned over 5 days of sessions comprising 11,359 s programmed with 9,282 in-person registrants and 3,284 virtual registrants. Posters and oral presentations were either in person, virtual or both, with live interaction possible either in a room and/or online. This report highlights some of the medicinal chemistry presentations delivered at the meeting. © 2022 Prous Science. All rights reserved.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenadogene nolparvovec. rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy Lenadogene nolparvovec。编码ND4的rAAV2基因治疗载体，治疗Leber遗传性视神经病变
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.6.3413456
L. Ferro Desideri, C. Traverso, M. Iester
{"title":"Lenadogene nolparvovec. rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy","authors":"L. Ferro Desideri, C. Traverso, M. Iester","doi":"10.1358/dof.2022.47.6.3413456","DOIUrl":"https://doi.org/10.1358/dof.2022.47.6.3413456","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pipeline on the Move - September 2022 管道在移动- 2022年9月
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.9.3474004
L.F. Betolin
{"title":"Pipeline on the Move - September 2022","authors":"L.F. Betolin","doi":"10.1358/dof.2022.47.9.3474004","DOIUrl":"https://doi.org/10.1358/dof.2022.47.9.3474004","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tanfanercept. Recombinant variant of human TNFR1, TNF-alpha modulator, Treatment of dry eye disease Tanfanercept。重组人TNFR1变异体，tnf - α调节剂，治疗干眼症
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.7.3413463
F. Biagini, L. Ferro Desideri, G. Giannaccare, C. Traverso, A. Vagge
{"title":"Tanfanercept. Recombinant variant of human TNFR1, TNF-alpha modulator, Treatment of dry eye disease","authors":"F. Biagini, L. Ferro Desideri, G. Giannaccare, C. Traverso, A. Vagge","doi":"10.1358/dof.2022.47.7.3413463","DOIUrl":"https://doi.org/10.1358/dof.2022.47.7.3413463","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paxalisib. PI3K/mTOR inhibitor, Treatment of gliomas Paxalisib。PI3K/mTOR抑制剂，治疗胶质瘤
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.1.3349022
Q. Chen, J. Wu, L. Tao, C. Ashby, L. Lin, Z. Chen
{"title":"Paxalisib. PI3K/mTOR inhibitor, Treatment of gliomas","authors":"Q. Chen, J. Wu, L. Tao, C. Ashby, L. Lin, Z. Chen","doi":"10.1358/dof.2022.47.1.3349022","DOIUrl":"https://doi.org/10.1358/dof.2022.47.1.3349022","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66440861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Heart Association (AHA) Scientific Sessions - 2021 Annual Meeting. Virtual - November 13-15, 2021 美国心脏协会(AHA)科学会议- 2021年年会。虚拟- 2021年11月13日至15日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.3.3393248
N. Díaz
{"title":"American Heart Association (AHA) Scientific Sessions - 2021 Annual Meeting. Virtual - November 13-15, 2021","authors":"N. Díaz","doi":"10.1358/dof.2022.47.3.3393248","DOIUrl":"https://doi.org/10.1358/dof.2022.47.3.3393248","url":null,"abstract":"The AHA Scientific Sessions, the annual meeting of the Amer-ican Heart Association, highlights the latest cutting-edge basic, translational and clinical research in cardiovascular diseases. This year, the conference took place virtually due to the COVID-19 pandemic and comprised several days of live sessions and on-demand virtual content, including posters and prerecorded presentations.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tebipenem pivoxil hydrobromide. Penicillin-binding protein (PBP) (bacterial) inhibitor, Carbapenem antibiotic, Treatment of urinary tract infections 氢溴化特比苯南酯。青霉素结合蛋白(PBP)(细菌)抑制剂，碳青霉烯类抗生素，尿路感染的治疗
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.5.3293606
M. N. Ahmad, C. Dasgupta, S. Chopra
{"title":"Tebipenem pivoxil hydrobromide. Penicillin-binding protein (PBP) (bacterial) inhibitor, Carbapenem antibiotic, Treatment of urinary tract infections","authors":"M. N. Ahmad, C. Dasgupta, S. Chopra","doi":"10.1358/dof.2022.47.5.3293606","DOIUrl":"https://doi.org/10.1358/dof.2022.47.5.3293606","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ciltacabtagene autoleucel. CAR-T therapy targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma Ciltacabtagene autoleucel。靶向b细胞成熟抗原(BCMA)的CAR-T疗法，治疗多发性骨髓瘤
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.4.3381589
S. Lee, A. Cowan
{"title":"Ciltacabtagene autoleucel. CAR-T therapy targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma","authors":"S. Lee, A. Cowan","doi":"10.1358/dof.2022.47.4.3381589","DOIUrl":"https://doi.org/10.1358/dof.2022.47.4.3381589","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信